LUPIN price chart
Daily close · 5-year history
Instrument details
Identifiers & classification
- Symbol
- LUPIN
- MB Code
- MBEQU2979
- ISIN
- INE326A01037
- BSE code
- 500257
- Industry group
- Pharmaceuticals & Biotechnology
- Screener
- View peers →
Latest earnings
Most recent declared quarter
- Quarter
- Mar 2026
- Revenue
- 7474.66 Cr
- Net profit
- 1468.67 Cr
- EPS
- 34.75
- YoY revenue
- +31.89%
Company documents
12 PDFs across 4 categories
Audited annual reports & financial statements
Earnings call transcripts & Q&A
Investor decks & strategy updates
Exchange filings & corporate announcements
Corporate timeline
Earnings, news & corporate actions for LUPIN
Lupin won USFDA approval for famotidine injection USP, 20 mg/2 mL, for ulcers and GERD; it will be made at Nagpur. The article also cites…
Lupin Ltd’s Q4 2026 earnings call highlighted record revenue and profit growth, while management warned of rising competition and outline…
Lupin shares fell despite reporting a 90% jump in Q4 profit and announcing its highest-ever dividend, highlighting a strong earnings beat…
Lupin said its US business should stay above $1 billion in FY27, with biosimilars, injectables and specialty products driving growth; it …
Lupin reported Q4 net profit up 88% to ₹1,468.67 crore and revenue up 32% to ₹7,474.66 crore, with record US sales of $371 million and a …
EPS 34.75 vs est. 27.42
Beat estimates by 26.73%
Lupin’s Q4FY26 net profit nearly doubled to ₹1,460 crore on strong US generics sales; FY26 profit rose 62.5% and revenue 23.1%, with a fi…
EPS 34.99 vs est. 28.64
Beat estimates by 22.18%
Price returns
Historical performance
Technicals
Indicator consensus